OrthoPediatrics Corp (KIDS) stock
KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/308% below fair value
$31.65+0.24 (+0.76%)
Close on Nov 18, 2026Market cap $826.40MP/E –Yield –
OrthoPediatrics r&d expenses
Research and development expenses are spending on new products and technology.
OrthoPediatrics's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.28M, down 4.9% year over year. For fiscal 2025 it was $9.10M, down 17.5% from the year before. Over ten years it grew 17.7% a year on average. The highest annual figure on record is $11.03M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.10M | -17.5% |
| FY2024 | Dec 31, 2024 | $11.03M | +1.3% |
| FY2023 | Dec 31, 2023 | $10.90M | +28.9% |
| FY2022 | Dec 31, 2022 | $8.45M | +52.5% |
| FY2021 | Dec 31, 2021 | $5.54M | +5.1% |
| FY2020 | Dec 31, 2020 | $5.27M | -8.3% |
| FY2019 | Dec 31, 2019 | $5.75M | +21.5% |
| FY2018 | Dec 31, 2018 | $4.73M | +38.2% |
| FY2017 | Dec 31, 2017 | $3.42M | +54.0% |
| FY2016 | Dec 31, 2016 | $2.22M | +24.3% |
| FY2015 | Dec 31, 2015 | $1.79M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.47M | +5.7% |
| Q2 FY2026 | Jun 30, 2026 | $2.33M | +7.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.23M | -5.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.26M | -22.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.33M | -9.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.16M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.35M | -21.6% |
| Q4 FY2024 | Dec 31, 2024 | $2.92M | -0.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.58M | +0.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.54M | -14.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.00M | +22.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.92M | +18.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.56M | +16.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.97M | +69.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.45M | +20.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.47M | +53.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.21M | +69.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.75M | +31.8% |
| Q1 FY2022 | Mar 31, 2022 | $2.03M | +55.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.61M | -21.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.30M | +20.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.33M | +50.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.31M | +3.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.05M | +7.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.08M | -22.9% |
| Q2 FY2020 | Jun 30, 2020 | $881.00K | -28.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.27M | +4.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.91M | +49.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.40M | +24.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.23M | +10.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.21M | -0.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.28M | +35.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.12M | -0.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.12M | +66.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.22M | +77.3% |
| Q4 FY2017 | Dec 31, 2017 | $941.00K | +50.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.13M | – |
| Q2 FY2017 | Jun 30, 2017 | $668.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $687.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $624.00K | – |
See a number that looks wrong?